Indication
Metastatic Castrate-Resistant Prostate Cancer
1 clinical trial
1 product
Clinical trial
Phase I, Open-Label Study of Dually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)Status: Recruiting, Estimated PCD: 2027-01-31
Product
TmPSMA-02